Polymorphic forms of rifaximin and clinical efficacy
Drug profileGastroent Hepatol 2025; 79(2): 131–133. doi: 10.48095/ccgh2025131
Literaturepdf Milan LukášIron carboxymaltose in the treatment of iron deficiency/anaemia in patients with IBD
Drug profileGastroent Hepatol 2025; 79(1): 58–64. doi: 10.48095/ccgh202558
Literaturepdf Michaela BachratáBiosimilar ustekinumab CT-P43
Drug profileGastroent Hepatol 2025; 79(1): 55–56. doi: 10.48095/ccgh202555
Literaturepdf Milan LukášTen years since the introduction of vedolizumab into clinical practice in inflammatory bowel diseases
Drug profileGastroent Hepatol 2024; 78(6): 492–493. doi: 10.48095/ccgh2024492
Literaturepdf Milan LukášCinitaprid expands treatment options for functional dyspepsia
Drug profileGastroent Hepatol 2024; 78(5): 441–443. doi: 10.48095/ccgh2024441
SummaryLiteraturepdf Jiří SlívaEtrasimod – the second generation S1P receptor modulators in ulcerative colitis therapy
Drug profileGastroent Hepatol 2024; 78(5): 415–416. doi: 10.48095/ccgh2024415
Literaturepdf Milan LukášGapulsid® (cinitapride) – the unique prokinetic indicated for the treatment of upper functional dyspepsia and gastroesophageal reflux disease
Drug profileGastroent Hepatol 2024; 78(4): 343–344. doi: 10.48095/ccgh2024343
Literaturepdf Luděk HrdličkaFirst experience with filgotinib in the upper line of treatment in patients with ulcerative colitis
Drug profileGastroent Hepatol 2024; 78(2): 170–172. doi: 10.48095/ccgh2024170
Literaturepdf Milan Lukáš, Dana ĎuricováMirikizumab – the first anti-IL23 p19 antibody in ulcerative colitis therapy
Drug profileGastroent Hepatol 2024; 78(1): 27–30. doi: 10.48095/ccgh202427
Literaturepdf Milan LukášFilgotinib in the treatment of inflammatory bowel diseases
Drug profileGastroent Hepatol 2023; 77(2): 145–146. doi: 10.48095/ccgh2023145
Literaturepdf Milan Lukáš